A phase 1/2 open-label study to evaluate safety and preliminary evidence of effectiveness of tumor ablation with talaporfin sodium (LS11) and interstitial light emitting diodes (LEDs) in the treatment of subjects with inoperable hepatocellular carcinoma (HCC).

Trial Profile

A phase 1/2 open-label study to evaluate safety and preliminary evidence of effectiveness of tumor ablation with talaporfin sodium (LS11) and interstitial light emitting diodes (LEDs) in the treatment of subjects with inoperable hepatocellular carcinoma (HCC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Talaporfin (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Light Sciences Oncology
  • Most Recent Events

    • 17 Jan 2008 Status changed from in progress to completed.
    • 09 Jan 2007 Status change
    • 21 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top